The discovery and advancement of treatments such as oral SERDs, oral CERANs, oral PROTAC, oral SERCA, and many others offer the possibility of more efficient and safer ER-targeted therapies for patients grappling with both early and late-stage ER+ breast cancers. The gene discussed is ESR1; the disease is breast carcinoma.